Cargando…
Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus
Current vaccines targeting surface proteins can drive antigenic variation resulting either in the emergence of more highly pathogenic viruses or of antigenically distinct viruses that escape control by vaccination and thereby persist in the host population. Influenza vaccines typically target the hi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605591/ https://www.ncbi.nlm.nih.gov/pubmed/23200938 http://dx.doi.org/10.1016/j.vaccine.2012.11.047 |
_version_ | 1782263919313682432 |
---|---|
author | Boyd, Amy C. Ruiz-Hernandez, Raul Peroval, Marylene Y. Carson, Connor Balkissoon, Devanand Staines, Karen Turner, Alison V. Hill, Adrian V.S. Gilbert, Sarah C. Butter, Colin |
author_facet | Boyd, Amy C. Ruiz-Hernandez, Raul Peroval, Marylene Y. Carson, Connor Balkissoon, Devanand Staines, Karen Turner, Alison V. Hill, Adrian V.S. Gilbert, Sarah C. Butter, Colin |
author_sort | Boyd, Amy C. |
collection | PubMed |
description | Current vaccines targeting surface proteins can drive antigenic variation resulting either in the emergence of more highly pathogenic viruses or of antigenically distinct viruses that escape control by vaccination and thereby persist in the host population. Influenza vaccines typically target the highly mutable surface proteins and do not provide protection against heterologous challenge. Vaccines which induce immune responses against conserved influenza epitopes may confer protection against heterologous challenge. We report here the results of vaccination with recombinant modified Vaccinia virus Ankara (MVA) and Adenovirus (Ad) expressing a fusion construct of nucleoprotein and matrix protein (NP + M1). Prime and boost vaccination regimes were trialled in different ages of chicken and were found to be safe and immunogenic. Interferon-γ (IFN-γ) ELISpot was used to assess the cellular immune response post secondary vaccination. In ovo Ad prime followed by a 4 week post hatch MVA boost was identified as the most immunogenic regime in one outbred and two inbred lines of chicken. Following vaccination, one inbred line (C15I) was challenged with low pathogenic avian influenza (LPAI) H7N7 (A/Turkey/England/1977). Birds receiving a primary vaccination with Ad-NP + M1 and a secondary vaccination with MVA-NP + M1 exhibited reduced cloacal shedding as measured by plaque assay at 7 days post infection compared with birds vaccinated with recombinant viruses containing irrelevant antigen. This preliminary indication of efficacy demonstrates proof of concept in birds; induction of T cell responses in chickens by viral vectors containing internal influenza antigens may be a productive strategy for the development of vaccines to induce heterologous protection against influenza in poultry. |
format | Online Article Text |
id | pubmed-3605591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Elsevier Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36055912013-03-22 Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus Boyd, Amy C. Ruiz-Hernandez, Raul Peroval, Marylene Y. Carson, Connor Balkissoon, Devanand Staines, Karen Turner, Alison V. Hill, Adrian V.S. Gilbert, Sarah C. Butter, Colin Vaccine Article Current vaccines targeting surface proteins can drive antigenic variation resulting either in the emergence of more highly pathogenic viruses or of antigenically distinct viruses that escape control by vaccination and thereby persist in the host population. Influenza vaccines typically target the highly mutable surface proteins and do not provide protection against heterologous challenge. Vaccines which induce immune responses against conserved influenza epitopes may confer protection against heterologous challenge. We report here the results of vaccination with recombinant modified Vaccinia virus Ankara (MVA) and Adenovirus (Ad) expressing a fusion construct of nucleoprotein and matrix protein (NP + M1). Prime and boost vaccination regimes were trialled in different ages of chicken and were found to be safe and immunogenic. Interferon-γ (IFN-γ) ELISpot was used to assess the cellular immune response post secondary vaccination. In ovo Ad prime followed by a 4 week post hatch MVA boost was identified as the most immunogenic regime in one outbred and two inbred lines of chicken. Following vaccination, one inbred line (C15I) was challenged with low pathogenic avian influenza (LPAI) H7N7 (A/Turkey/England/1977). Birds receiving a primary vaccination with Ad-NP + M1 and a secondary vaccination with MVA-NP + M1 exhibited reduced cloacal shedding as measured by plaque assay at 7 days post infection compared with birds vaccinated with recombinant viruses containing irrelevant antigen. This preliminary indication of efficacy demonstrates proof of concept in birds; induction of T cell responses in chickens by viral vectors containing internal influenza antigens may be a productive strategy for the development of vaccines to induce heterologous protection against influenza in poultry. Elsevier Science 2013-01-11 /pmc/articles/PMC3605591/ /pubmed/23200938 http://dx.doi.org/10.1016/j.vaccine.2012.11.047 Text en © 2013 Elsevier Ltd. https://creativecommons.org/licenses/by/3.0/ Open Access under CC BY 3.0 (https://creativecommons.org/licenses/by/3.0/) license |
spellingShingle | Article Boyd, Amy C. Ruiz-Hernandez, Raul Peroval, Marylene Y. Carson, Connor Balkissoon, Devanand Staines, Karen Turner, Alison V. Hill, Adrian V.S. Gilbert, Sarah C. Butter, Colin Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus |
title | Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus |
title_full | Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus |
title_fullStr | Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus |
title_full_unstemmed | Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus |
title_short | Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus |
title_sort | towards a universal vaccine for avian influenza: protective efficacy of modified vaccinia virus ankara and adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605591/ https://www.ncbi.nlm.nih.gov/pubmed/23200938 http://dx.doi.org/10.1016/j.vaccine.2012.11.047 |
work_keys_str_mv | AT boydamyc towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT ruizhernandezraul towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT perovalmaryleney towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT carsonconnor towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT balkissoondevanand towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT staineskaren towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT turneralisonv towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT hilladrianvs towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT gilbertsarahc towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus AT buttercolin towardsauniversalvaccineforavianinfluenzaprotectiveefficacyofmodifiedvacciniavirusankaraandadenovirusvaccinesexpressingconservedinfluenzaantigensinchickenschallengedwithlowpathogenicavianinfluenzavirus |